大洋洲 · 区域市场 · The Motley Fool Australia
Telix Pharmaceuticals Q3 2026 earnings: revenue up, pipeline advances
Telix Pharmaceuticals' Q3 2026 update sees strong revenue growth, FDA milestones, and a major merger to expand its radiopharmaceuticals platform. The post Telix Pharmaceuticals Q3…
在 The Motley Fool Australia 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.fool.com.au)



